InnoCare Pharma RMB2.9 billion Shanghai IPO
This is the largest A-share listing by an overseas-listed biotechnology company in 2022 so far
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Tencent Music Entertainment Group secondary listing
We advised Tencent Music Entertainment Group on its secondary listing by way of introduction on the HKEX
Interra Acquisition HK$1 billion IPO
We advised the SPAC on its IPO and HKEX listing
Mitsubishi HC Capital $500 million senior notes offering
We advised Mitsubishi HC Capital on its senior notes offering
Sumitomo Mitsui Trust Bank $1 billion senior notes offering
We advised Sumitomo Mitsui Trust Bank on the update of its global MTN program and senior notes offering
Norinchukin Bank $1 billion senior notes offering
The senior notes are due 2027 and 2032
Mizuho Financial Group $1.75 billion senior notes offering
The senior callable fixed-to-fixed reset rate notes are due 2028 and 2033
Biocytogen HK$549 million IPO
We advised Biocytogen on its IPO and HKEX listing
Red Star Macalline Group $249.7 million credit enhanced bonds offering
We advised the issuer on the credit enhanced bonds offering
NTT Finance $1.5 billion senior notes offering
The green bonds were issued in three tranches